Competition weekly news summary
Friday, March 2, 2012

Conferences and Speeches

  • "Competition policy and growth"
    European Parliament, Internal Market and Consumer protection Committee, Brussels, Joaquín Almunia
    28 February 2012
    "Competition policy aims to promote growth by removing obstacles to change. It also relies on the principle that markets are more dynamic and growth friendly when many actors are free to enter and do business. We do not want a world of large behemoths protected by the fact that they carry national flags. Honestly, I do not believe there was ever a time when this model was successful. Today, the model is particularly ill suited to a technological revolution that is based on interconnection, participation, rapid change and flexibility."
    Read full speech >


  • ECN brief - first issue 2012
    29 February 2012
    The European Competition Network (ECN) has published its first news brief for 2012. This issue reports on several antitrust cases directly relating to consumer products (detergents, pharmaceutical products, fruits and vegetables) as well as a wide range of legislation and policy initiatives.
    Go to ECN brief 1/2012 >


  • Commission opens proceedings against MathWorks
    1 March 2012
    The Commission has opened an investigation to assess whether The MathWorks Inc., a U.S. based software company, has distorted competition in the market for the design of commercial control systems by preventing competitors from achieving interoperability with its products. The Commission will investigate whether by allegedly refusing to provide a competitor with end-user licences and interoperability information, the company has breached EU antitrust rules that prohibit the abuse of a dominant position.
    Read more >
  • Commission closes investigation in pharmaceutical companies AstraZeneca and Nycomed
    1 March 2012
    The Commission has ceased its antitrust investigation into the pharmaceutical companies AstraZeneca and Nycomed. The investigation focused on suspected individual or joint action to delay the market entry of generic medicines.
    Read more >



Editorial and legal information

Published by the Competition Directorate General of the European Commission. The content of this publication does not necessarily reflect the official position of the European Commission. Neither the Commission nor any person acting on its behalf is responsible for the use which might be made of the above information.

© European Union, 2012. Reproduction is authorised provided the source is acknowledged.

Competition website